alexa
Reach Us +44-1993-227344
Chemotherapy in the Treatment of Ovarian Psammocarcinoma: A Case Report and Review of the Literature | OMICS International
ISSN: 2165-7920
Journal of Clinical Case Reports
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Chemotherapy in the Treatment of Ovarian Psammocarcinoma: A Case Report and Review of the Literature

Adil Debbagh1,2*, Mohamed Reda Khmamouche1, Mohamed Allaoui3, Mohamed Ichou1 and Hassan Errihani2
1Medical Oncology Department, Military Hospital Mohamed V, Rabat, Morocco
2Medical Oncology Department, National Institute of Oncology, Rabat, Morocco
3Anatomopathology Department, Military Hospital Mohamed V, Rabat, Morocco
Corresponding Author : Adil Debbagh
Medical Oncology Department
National Institute of Oncology
Military Hospital Mohamed V, Rabat, Morocco
E-mail: [email protected]
Received February 16, 2013; Accepted Septeber 13, 2013; Published September 16, 2013
Citation: Debbagh A, Khmamouche MR, Allaoui M, Ichou M, Errihani H (2013) Chemotherapy in the Treatment of Ovarian Psammocarcinoma: A Case Report and Review of the Literature. J Clin Case Rep 3:303. doi:10.4172/2165-7920.1000303
Copyright: © 2013 Debbagh A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Clinical Case Reports

Abstract

Introduction: Psammocarcinoma is a rare form of epithelial serous ovarian carcinoma characterized by extensive formation of psammoma bodies, invasion of ovarian stroma, peritoneum or intraperitoneal viscera, and moderate cytological atypia. These tumors represent a real problem of the diagnostic, and the role of chemotherapy is not yet clearly demonstrated.

Case presentation: We herein report a case of psammocarcinoma of ovary with peritoneal carcinosis in a forty year old Moroccan female. The patient underwent optimal surgical debulking and nine courses of chemotherapy with carboplatinum and paclitaxel with a complete response. The prognosis for this type of ovarian cancer is unclear, but it appears to be better than other forms of epithelial ovarian cancer.

Conclusion: The psammocarcinome is a rare entity, majority of patients are diagnosed at an advanced stage. The role of chemotherapy is poorly defined; some authors have their patients treated by neoadjuvant or adjuvant chemotherapy.

We currently lack evidence of increasing the benefits that can bring chemotherapy in the management of advanced ovarian psammocarcinomas. Only trials in wide yard can answer this question.

Keywords
Psammocarcinoma; Ovarian; Complete response
Introduction
Psammocarcinoma is a rare form of epithelial serous ovarian carcinoma characterized by extensive formation of psammoma bodies, invasion of ovarian stroma, peritoneum or intraperitoneal viscera, and moderate cytological atypia [1]. These tumors represent a real diagnostic problem, of the fact that there are not clinical and pathological features that allow us to differentiate serous borderline [2].
There are no therapeutic standard guiding the management of psammocarcinomas in the advanced stages, and the role of chemotherapy is not yet clearly demonstrated.
The authors reported a case of an ovarian psammocarcinoma diagnosed at an advanced stage and was successfully treated only by chemotherapy.
Case Report
A 40 year old woman, diabetic, hypertensive under treatment for 10 years, its history back by the sudden onset of abdominal pain, diffuse pelvic evolving in a context of deterioration of general condition. The Physical examination in the admission reveals a patient with a performance status at 2. Pelvic examination showed a sensitive voluminous abdominopelvic mass with abundance ascitis. Abdomino pelvic computed tomography scan revealed a heavily calcified abdominopelvic mass with peritoneal carcinosis. The serum CA-125 level was elevated (400 UI/ml; normal value: <35 UI/ml). The patient underwent a surgical exploration which revealed generalized carcinosis.
The biopsy of the mass of the left ovary revealed a psammocarcinoma (Figure 1). She was then referred to our department for treatment. Primary chemotherapy was planned. The patient received three courses of paclitaxel 175 mg/m2 and carboplatin (AUC 5).
Evaluation after 3 cycles showed a net clinical benefit with radiological stabilisation in the Chest Abdominal and pelvic CT scan. The decision was to continue the same chemotherapy.
The patient received three other courses, evaluation showed a net clinical benefit with a performance status at 1, the disappearance of the pain and drainage of ascitis.
The CA125 level went from 400 to 50 IU, and we had a radiological stabilization with no other distant lesions. The patient has been proposed for revision surgery but because the radiological stabilization, and the good tolerability of the treatment, we decided to continue the chemotherapy. Evaluation after 9 cycles of chemotherapy objectified a complete clinical response and normalization of the level of CA125 (Table 1) but always radiological stabilization.
Discussion
The psammocarcinome is a rare entity that more frequently localized in the thyroid [3], Meninges [4] and at the extended gastrointestinal [5,6]. Its localization except ovarian and limited to a few cases reported in the literature [7-9]. Histological diagnosis is difficult, it uses criteria determined by morphological Gilks which should be sought as extensive training bodies of psammoma which appear calcified, rolled, invasion of ovarian stroma and a typical cytology moderate [7,10], it is the case of our patient in whom the diagnosis of ovarian psammocarcinoma could not be carried after a second reading. Majority of patients are diagnosed at an advanced stage as in the case series Gilks and other series [11-14]. Because of their rarity there are no specific recommendations treatment, most authors recommend aggressive cytoreduction [15]. The role of chemotherapy is poorly defined; some authors have their patients treated by neoadjuvant or adjuvant chemotherapy. The care of patients who cannot benefit from surgical treatment to be defined in particular the role of chemotherapy.
Kelley et al. [11] reported in their work (Table 2) series of 12 cases treated by surgery or surgery and chemotherapy and conclude a possible benefit of adjuvant chemotherapy in aggressive forms.
By referring to the treatment of peritoneal psamocarconomes is described in the literature including different sets of patients were treated with neoadjuvant, adjuvant or consolidation chemotherapy with the disease often diagnosed at an advanced stage, the results showed in most cases, a regression of the disease but the period of regression varied from one case al depending on the type of surgery done to the chemotherapy regimen adopted as shown (Table 3).
There is no limit to our research of cases treated with chemotherapy alone, the case report was distinguished by an excellent clinical and biological response form of advanced ovarian psammocarcinoma.
Conclusion
The standard treatment of ovarian psammocarcinoma is surgery and few cycles of chemotherapy in post operative in the aggressive forms, however, we currently lack evidence of increasing the benefits that can bring chemotherapy in the management of advanced ovarian psammocarcinomas. Only trials in wide yard can answer this question.
References

Tables and Figures at a glance

Table icon Table icon Table icon
Table 1 Table 2 Table 3

 

Figures at a glance

Figure
Figure 1
Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Article Usage

  • Total views: 11827
  • [From(publication date):
    September-2013 - Nov 18, 2018]
  • Breakdown by view type
  • HTML page views : 8052
  • PDF downloads : 3775
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri and Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version